Use of drug treatments for Alzheimer's disease in France: a study on a national level based on the National Alzheimer's Data Bank (Banque Nationale Alzheimer)
Authors:
- Karim TifrateneKTKarim Tifratene
- Franck Le DuffFDFranck Le Duff
- Catherine QuantinCQCatherine Quantin
- The Participating CentresTCThe Participating Centres
- 20 June 2012
- journal article
- research article
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 21 (9) , 1005-1012
Abstract
Purpose: To examine the way in which specific drug treatments for Alzheimer's disease are used and whether their use complies with clinical practice guidelines issued by the French National Authority for Health in patients with Alzheimer's disease.Methods: We analysed a cross‐section of the French National Alzheimer's databank (BNA). Participants were individuals who consulted centres contributing to the BNA in 2010 and diagnosed with Alzheimer's disease and with at least one Mini Mental State Examination (MMSE) score recorded during the course of the year.Results: Of 191 919 consultations recorded in the database, 29.9% involved a diagnosis of Alzheimer's disease, and 26 809 patients had completed at least one MMSE. In 76.9% of cases, treatment was given with an anti‐Alzheimer's drug. Monotherapy with an acetylcholinesterase inhibitor was prescribed for 48.3% of patients, monotherapy with memantine in 14.2% and dual therapy in 14.4% of cases. Treatment given did not comply with the guidelines in 20.7% of cases. Prescriptions not complying with the guidelines were associated with a lower mean MMSE score (13.6 vs. 18.0; p < 0.00001) and more cases of treatment with antidepressants (29.2% vs. 22.8%; p < 0.00001), anxiolytics (14.7% vs. 12.3%; p < 0.00001) and antipsychotics (8.7% vs. 4.9%; p < 0.00001).Conclusion: Four of five prescriptions for treatment with anti‐Alzheimer's drugs complied with the specific drug treatment chapter of the 2008 French clinical guidelines. Prescriptions not complying with the guidelines for acetylcholinesterase inhibitors and memantine were usually issued in situations involving advanced‐stage Alzheimer's disease. The BNA can provide precise information on medical practice in Alzheimer's disease and related disorders. Copyright © 2012 John Wiley & Sons, Ltd.Keywords
This publication has 21 references indexed in Scilit:
- The 2008–2012 French Alzheimer Plan: Description of the National Alzheimer Information SystemJournal of Alzheimer’s Disease, 2012
- Alzheimer's diseaseThe Lancet, 2011
- Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer diseaseJournal of Neurology, Neurosurgery & Psychiatry, 2009
- Long-term Course and Effectiveness of Combination Therapy in Alzheimer DiseaseAlzheimer Disease & Associated Disorders, 2008
- Prevalence of cholinesterase inhibitors in subjects with dementia in EuropePharmacoepidemiology and Drug Safety, 2008
- Memantine Therapy for Alzheimer Disease in Real-world PracticeAlzheimer Disease & Associated Disorders, 2008
- Risk of Death With Atypical Antipsychotic Drug Treatment for DementiaJAMA, 2005
- Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trialsBMJ, 2005
- Alzheimer's DiseaseNew England Journal of Medicine, 2004
- Clinical guidelines: Potential benefits, limitations, and harms of clinical guidelinesBMJ, 1999